Quick Takeaways
- GILEAD SCIENCES, INC. filed SCHEDULE 13D/A for Galapagos NV Ordinary Shares, no par value (GLPG).
- Disclosed ownership: 30%.
- Date of event: 07 Jan 2025.
GILEAD SCIENCES, INC. - 07 Jan 2025 SCHEDULE 13D/A Report for Galapagos NV Ordinary Shares, no par value (GLPG)
- Filing Manager
- GILEAD SCIENCES, INC.
- Reporting Manager
- Gilead Sciences, Inc.
- Symbol
- GLPG
- Shares outstanding
- 70,170,602 shares
- Disclosed Ownership
- 20,981,010 shares
- Ownership
- 30%
- Form type
- SCHEDULE 13D/A
- Filing time
- 10 Jan 2025, 15:46:26 UTC
- Date of event
- 07 Jan 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"GILEAD SCIENCES, INC. disclosed 30% ownership in Galapagos NV Ordinary Shares, no par value (GLPG) on 07 Jan 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 10 Jan 2025, 15:46.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 30% | 20,981,010 | 0 | 20,981,010 | /s/ Andrew D. Dickinson | Andrew D. Dickinson, Executive Vice President and Chief Financial Officer | 0000882095 |
| Gilead Therapeutics A1 Unlimited Company | 30% | 20,981,010 | 0 | 20,981,010 | /s/ Aoife Marrinan | Aoife Marrinan, Director |